# Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer

> **NCT01531595** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pia Osterlund** · enrollment: 100 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab plus alternating XELOX/XELIRI

## Key facts

- **NCT ID:** NCT01531595
- **Lead sponsor:** Pia Osterlund
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-02
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01531595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01531595, "Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01531595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*